DK1363938T3 - Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen - Google Patents

Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen Download PDF

Info

Publication number
DK1363938T3
DK1363938T3 DK01956081.2T DK01956081T DK1363938T3 DK 1363938 T3 DK1363938 T3 DK 1363938T3 DK 01956081 T DK01956081 T DK 01956081T DK 1363938 T3 DK1363938 T3 DK 1363938T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
cells
cell
antigen
polypeptide
Prior art date
Application number
DK01956081.2T
Other languages
Danish (da)
English (en)
Inventor
Tzyy-Choou Wu
Chien-Fu Hung
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK1363938T3 publication Critical patent/DK1363938T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
DK01956081.2T 2000-08-03 2001-08-02 Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen DK1363938T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22290200P 2000-08-03 2000-08-03
PCT/US2001/024134 WO2002012281A2 (en) 2000-08-03 2001-08-02 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen

Publications (1)

Publication Number Publication Date
DK1363938T3 true DK1363938T3 (en) 2014-03-24

Family

ID=22834209

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01956081.2T DK1363938T3 (en) 2000-08-03 2001-08-02 Molecular vaccine that connects an endoplasmic reticulum-chaperonepolypeptid with an antigen

Country Status (8)

Country Link
US (3) US7342002B2 (enExample)
EP (1) EP1363938B1 (enExample)
JP (2) JP5087201B2 (enExample)
AU (1) AU2001278117A1 (enExample)
CA (1) CA2417214C (enExample)
DK (1) DK1363938T3 (enExample)
ES (1) ES2454640T3 (enExample)
WO (1) WO2002012281A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
WO2002009645A2 (en) * 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2004092221A1 (ja) * 2003-04-18 2004-10-28 Sekisui Chemical Co. Ltd. 免疫原及び免疫用組成物、並びにそれらを使用する抗体の製造方法
EP1644048B1 (en) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
CN1833030B (zh) 2003-05-22 2014-07-23 美国弗劳恩霍夫股份有限公司 用于表达、传递及纯化目标多肽的重组载体分子
WO2005081716A2 (en) * 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
JP2007528838A (ja) * 2003-12-24 2007-10-18 ライデン ユニバーシティ メディカル センター 腫瘍特異的ワクチンとしての合成タンパク質
KR101215780B1 (ko) 2004-10-15 2012-12-26 죠 지바 동물의 면역 방법, 면역용 조성물, 항체의 제조 방법,하이브리도마의 제조 방법 및 모노클로날 항체의 제조 방법
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) * 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin
EP1919504B1 (en) * 2005-08-03 2013-10-16 iBio, Inc. Antibody to bacillus anthracis protective antigen
WO2007095320A2 (en) * 2006-02-13 2007-08-23 Fraunhofer Usa, Inc. Hpv antigens, vaccine compositions, and related methods
WO2008048344A2 (en) * 2006-02-13 2008-04-24 Fraunhofer Usa, Inc. Bacillus anthracis antigens, vaccine compositions, and related methods
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
WO2008119024A1 (en) * 2007-03-27 2008-10-02 University Of Florida Research Foundation Inc. Modified antigen presenting cells and methods of use
US8404252B2 (en) 2007-07-11 2013-03-26 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
JP2011518115A (ja) * 2008-01-28 2011-06-23 タップイミューン インコーポレイテッド 免疫応答を増強するためのタパシン増加
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods
WO2010030861A2 (en) * 2008-09-11 2010-03-18 Calretex, Llc Compositions and methods for purifying calreticulin
WO2010037046A1 (en) 2008-09-28 2010-04-01 Fraunhofer Usa, Inc. Humanized neuraminidase antibody and methods of use thereof
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
US10487332B2 (en) * 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
AU2012220592A1 (en) * 2011-02-23 2013-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Service Combined cell based GP96-IG-SIV/HIV, recombinant GP120 protein vaccination for protection from SIV/HIV
LT2714071T (lt) * 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
JP5981921B2 (ja) * 2011-09-02 2016-08-31 株式会社カネカ 小胞体シャペロンプロモータを用いた外来遺伝子を発現するトランスジェニック鳥類
WO2013093629A2 (en) * 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014164727A1 (en) * 2013-03-12 2014-10-09 Wisconsin Alumni Research Foundation A method of treating fungal infection
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017155981A1 (en) * 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7722629B2 (ja) 2017-07-04 2025-08-13 キュアバック エスイー 新規核酸分子
CN109182339A (zh) * 2018-09-06 2019-01-11 青岛农业大学 一种许氏平鮋钙网蛋白基因及应用
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744133A (en) 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US4898730A (en) 1987-03-13 1990-02-06 The University Of British Columbia Method to stimulate the immune response to specific antigens
US5582831A (en) 1991-11-26 1996-12-10 Yeda Research And Development Co., Ltd. Anti-tumor vaccines
ATE127345T1 (de) 1988-06-15 1995-09-15 Whitehead Biomedical Inst Stressproteine und verwendungen dafür.
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
DE3907721A1 (de) 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5545727A (en) 1989-05-10 1996-08-13 Somatogen, Inc. DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin
US5348945A (en) 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
US5821088A (en) 1990-05-11 1998-10-13 Siga Pharmaceuticals, Inc. Use of gram-positive bacteria to express recombinant proteins
AU8762991A (en) 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
ES2193133T3 (es) 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
GB9207701D0 (en) 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
IL106760A (en) 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5618536A (en) 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5997869A (en) 1993-03-15 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Peptides containing a fusion joint of a chimeric protein encoded by DNA spanning a tumor-associated chromosomal translocation and their use as immunogens
GB9306731D0 (en) 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
US5426097A (en) 1993-04-06 1995-06-20 The Trustees Of Columbia University In The City Of New York Calreticulin: a novel antithrombotic agent
EP0700445B1 (en) 1993-06-04 2002-01-23 Whitehead Institute For Biomedical Research Stress proteins and uses therefor
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5591716A (en) 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
EP0659438A1 (en) 1993-12-23 1995-06-28 Boehringer Mannheim Gmbh Conjugates consisting of peptidic T cell antigens and cell binding groups, and their use for therapy
US5750119A (en) 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
AUPM566794A0 (en) 1994-05-17 1994-06-09 University Of Queensland, The Process and product
US5854202A (en) 1995-01-24 1998-12-29 Dedhar; Shoukat Peptide fragments of calreticulin, peptide mimetics thereof, and pharmaceutical compostions comprising same
WO1996036643A1 (en) 1995-05-17 1996-11-21 University Of Alberta Method of inhibiting restenosis using calreticulin
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
JPH11510046A (ja) 1995-07-21 1999-09-07 ローヌ−プーラン ローラー ファーマシューティカルズ インコーポレイテッド アデノ関連ウイルスリポソーム及び樹状細胞をトランスフェクトして特異性免疫を刺激することにおけるそれらの使用
JP4163253B2 (ja) 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
DE19534348C2 (de) 1995-09-15 1997-07-10 Wieland Heinrich Prof Dr Med Verfahren zur Bestimmung von Autoimmunphänomenen
WO1997020854A1 (en) * 1995-12-05 1997-06-12 University Of Massachusetts Recombinant gas vesicles and uses thereof
AU734196B2 (en) 1996-03-28 2001-06-07 Whitehead Institute Opsonin-enhanced cells, and methods of modulating an immune response to an antigen
DE69723434T2 (de) 1996-04-26 2004-05-19 Rijksuniversiteit Te Leiden Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope
US5951975A (en) 1996-06-28 1999-09-14 University Of Pittsburgh Induction of CTLs specific for natural antigens by cross priming immunization
EP0950061A4 (en) 1996-09-20 2000-04-12 Univ New Mexico Heat shock protein complexes
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
DE69735376T2 (de) 1996-11-26 2006-12-14 Stressgen Biotechnologies Corp., Victoria Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort
US6046158A (en) 1996-12-20 2000-04-04 Board Of Regents The University Of Texas Systems Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
AU7022898A (en) 1997-04-23 1998-11-13 Ontario Cancer Treatment & Research Foundation Calreticulin-deficient cells
US6319503B1 (en) 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
HUP0003601A3 (en) 1997-08-05 2003-03-28 Stressgen Biotechnologies Corp Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
WO1999007869A1 (en) 1997-08-05 1999-02-18 University Of Florida Live recombinant vaccine comprising inefficiently or non-replicating virus
US6007821A (en) 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6331388B1 (en) 1997-10-17 2001-12-18 Wisconsin Alumni Research Foundation Immune response enhancer
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6534482B1 (en) 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
IL140239A0 (en) 1998-06-17 2002-02-10 Beth Israel Hospital Anti-angiogenic proteins and methods of use thereof
AU766403C (en) 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US6734173B1 (en) * 1999-10-20 2004-05-11 Johns Hopkins University HSP DNA vaccines
DE60038622D1 (de) 1999-10-20 2008-05-29 Univ Johns Hopkins Med Chimäre immunogene zusammensetzungen und dafür kodierende nukleinsäure
US20010034042A1 (en) 2000-01-20 2001-10-25 Srivastava Pramod K. Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
US6967075B2 (en) 2000-04-07 2005-11-22 Schering Corporation HCV replicase complexes
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
KR100919266B1 (ko) 2000-06-26 2009-09-30 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법
WO2002009645A2 (en) 2000-08-01 2002-02-07 The Johns Hopkins University Intercellular transport protein linked to an antigen as a molecular vaccine
EP1363938B1 (en) 2000-08-03 2013-12-11 Johns Hopkins University Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
JP3930243B2 (ja) * 2000-11-06 2007-06-13 本田技研工業株式会社 マグネットポンプ
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
WO2002061113A2 (en) 2001-02-01 2002-08-08 The Johns Hopkins University Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2002074920A2 (en) 2001-03-16 2002-09-26 Johns Hopkins University A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same
US20030144221A1 (en) 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
EP1417353A4 (en) 2001-07-20 2005-08-03 Univ Texas METHODS AND COMPOSITIONS ASSOCIATED WITH HPV ASSOCIATED PENCILS AND CANNULAR WELLS, INCLUDING CIN
US20060040262A1 (en) 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
AU2003224732A1 (en) 2002-03-25 2003-10-13 The Trustees Of Boston University Method of using anti-apoptotic factors in gene expression
CA2499837C (en) 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
US20070026076A1 (en) * 2003-02-24 2007-02-01 Tzyy-Choou Wu Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
EP1644048B1 (en) 2003-05-05 2015-04-29 Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
WO2005081716A2 (en) 2003-11-24 2005-09-09 The Johns Hopkins University DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
WO2006073970A2 (en) 2005-01-06 2006-07-13 The Johns Hopkins University Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines
WO2006081323A2 (en) 2005-01-26 2006-08-03 The Johns Hopkins University Anti-cancer dna vaccine employing plasmids encoding mutant oncoprotein antigen and calreticulin

Also Published As

Publication number Publication date
WO2002012281A2 (en) 2002-02-14
JP2004527213A (ja) 2004-09-09
EP1363938A2 (en) 2003-11-26
US8007781B2 (en) 2011-08-30
US20090148471A1 (en) 2009-06-11
CA2417214C (en) 2016-06-21
JP5087201B2 (ja) 2012-12-05
ES2454640T3 (es) 2014-04-11
US20050054820A1 (en) 2005-03-10
WO2002012281A3 (en) 2003-07-10
CA2417214A1 (en) 2002-02-14
JP2009017883A (ja) 2009-01-29
US20130203961A1 (en) 2013-08-08
US7342002B2 (en) 2008-03-11
EP1363938B1 (en) 2013-12-11
WO2002012281A9 (en) 2003-03-06
AU2001278117A1 (en) 2002-02-18

Similar Documents

Publication Publication Date Title
EP1363938B1 (en) Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
EP1222289B1 (en) Chimeric immunogenic compositions and nucleic acids encoding them
Velders et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
US7318928B2 (en) Molecular vaccine linking intercellular spreading protein to an antigen
WO2009002418A2 (en) T-cell peptide epitopes from carcinoembryonic antigen, immunogenic analogs, and uses thereof
KR20020068040A (ko) 키메라 면역원성 조성물 및 그들을 암호화하는 핵산
EP1644048B1 (en) Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
KR101195400B1 (ko) 암배아 항원 융합물 및 이의 용도
JP2004527213A5 (enExample)
WO2019101062A1 (zh) 重组疫苗及其应用
US20080260765A1 (en) HPV DNA Vaccines and Methods of Use Thereof
JP2008528004A (ja) 突然変異癌タンパク質抗原およびカルレティキュリンをコードするプラスミドを用いる抗癌ｄｎａワクチン
JP5854604B2 (ja) Ｉｇ−ｐＣｏｎｓｅｎｓｕｓ遺伝子ワクチン接種は、自己免疫疾患における抗体依存性の免疫病態から保護する
JP2007505601A (ja) ワクチン
JP2005526511A (ja) ワクチン
Li Development of multiple formulations of heat shock protein based vaccines for cancer immunotherapy